Related Experiment Video
Updated: Apr 6, 2026
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
3.0K
Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy.
1Molecular Immunology Section, National Eye Institute, National Institutes of Health, Building 10, Room 10N109A, 10 Center Drive, Bethesda, MD 20892-1857, USA. egwuaguc@nei.nih.gov.
Current Molecular Medicine
|August 5, 2015
Summary
Uveitis, an inflammatory eye disease causing vision loss, involves immune cells and cytokines. New therapies aim for safer, targeted treatments beyond corticosteroids to preserve sight.
Area of Science:
- Ophthalmology
- Immunology
- Pathology
Background:
- Uveitis is a significant cause of visual impairment, accounting for over 10% of severe visual handicaps in the US.
- Pathology involves intraocular inflammation due to immune cells and cytotoxic cytokines.
- Current treatments like corticosteroids have adverse effects, driving the need for novel therapies.
Purpose of the Study:
- To review the pathophysiology and molecular mechanisms of uveitis.
- To discuss emerging therapeutic strategies for uveitis.
Main Methods:
- Literature review summarizing current understanding of uveitis.
- Analysis of molecular mechanisms driving uveitis initiation and progression.
Main Results:
- Uveitis pathogenesis involves complex immune responses within the eye.
- Existing therapies have limitations and side effects.
Conclusions:
- Understanding uveitis molecular mechanisms is key to developing targeted treatments.
- Emerging strategies offer promise for more effective and safer uveitis management.
Related Concept Videos
01:22Microbiome of the Eye
38
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
38
01:27Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
01:23Ophthalmic Drug Delivery Systems
223
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
223
01:25Glaucoma: Overview
1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K